Eco Animal Health (LSE:EAH) has introduced ECOVAXXIN MS across the European Union, marking the commercial debut of the first vaccine developed through the company’s own research and development programme. The vaccine is designed to protect future layer and breeder chickens from four weeks of age against Mycoplasma synoviae, helping to reduce air-sac and foot-pad lesions while limiting egg production losses that can range from 5% to 10% in affected flocks.
Commercial rollout backed by established distribution network
The company is leveraging the sales infrastructure created for its flagship Aivlosin brand, together with strategic distribution partners, to support the rollout across key European poultry markets representing more than 220 million layer birds each year. Eco Animal Health believes the launch will provide significant health benefits for poultry producers while expanding its presence in the growing vaccine market. The group is also seeking regulatory approvals in the United States, Latin America and Asia as part of its international expansion strategy.
Proprietary R&D pipeline reaches commercial milestone
The launch of ECOVAXXIN MS represents an important milestone for Eco Animal Health, demonstrating its ability to bring internally developed innovations from the research stage to commercial markets. The addition of a proprietary vaccine broadens the company’s portfolio beyond its established antibiotic products, supporting greater revenue diversification while addressing increasing demand for effective disease prevention solutions in commercial livestock production.
Although the company continues to build momentum through product development and positive corporate progress, its relatively high valuation and uneven financial performance suggest investors will be looking for continued execution to justify future growth expectations.
More about Eco Animal Health
Eco Animal Health Group is a UK-based animal health company specialising in the development and commercialisation of veterinary pharmaceuticals for the poultry and pig industries. Operating in more than 70 countries and employing over 200 people, the company is best known for its patented antibiotic Aivlosin, which is used to treat respiratory and intestinal diseases in livestock.
Alongside its established medicines portfolio, Eco Animal Health has continued to invest in a proprietary research and development pipeline focused on vaccines and other animal health technologies. The business combines in-house innovation with an established commercial network and strategic distribution partnerships to bring new products to market.
The company’s growth strategy centres on expanding its presence in major livestock markets across Europe while pursuing approvals for new products in the United States, Latin America and Asia. Through this approach, Eco Animal Health aims to strengthen its position as a specialist provider of disease management solutions for commercial livestock producers.
Leave a Reply